Human trials to test efficacy and safety of genetic introduction of telomerase
First-in-human study aims to deliver viral vectors with hTERT gene in five individuals aged 45+.
Goal is to extend the telomeres to prevent, delay, or even reverse ageing.
Adeno-associated virus containing gene expressing telomerase reverse transcriptase will be injected.
Will be given as a single intravenous injection, followed by six safety and efficacy evaluations.
Risk of oncogenicity of AAVs with hTERT gene as there is telomerase upregulation in cancers.
Trials will be conducted by Libella Gene Therapeutics.
Mentioned in this article:
Libella Gene Therapeutics - Research institute in the field of gene therapy that is based in Manhattan, USA